Millennium Management LLC acquired a new stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 118,861 shares of the company's stock, valued at approximately $490,000. Millennium Management LLC owned about 0.20% of Eledon Pharmaceuticals at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Tower Research Capital LLC TRC grew its holdings in shares of Eledon Pharmaceuticals by 418.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company's stock worth $33,000 after purchasing an additional 6,412 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Eledon Pharmaceuticals by 8.3% in the 4th quarter. Renaissance Technologies LLC now owns 147,173 shares of the company's stock worth $606,000 after buying an additional 11,300 shares during the last quarter. Alpine Global Management LLC bought a new stake in shares of Eledon Pharmaceuticals in the 4th quarter worth approximately $56,000. Charles Schwab Investment Management Inc. raised its holdings in shares of Eledon Pharmaceuticals by 100.1% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 29,987 shares of the company's stock valued at $124,000 after acquiring an additional 15,000 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC raised its holdings in shares of Eledon Pharmaceuticals by 1.1% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 1,515,750 shares of the company's stock valued at $6,245,000 after acquiring an additional 15,750 shares in the last quarter. 56.77% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Separately, Wall Street Zen lowered shares of Eledon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, June 6th.
Check Out Our Latest Report on ELDN
Eledon Pharmaceuticals Stock Performance
Shares of ELDN stock remained flat at $3.00 on Thursday. The stock had a trading volume of 120,014 shares, compared to its average volume of 274,998. The stock's 50-day simple moving average is $3.04 and its 200 day simple moving average is $3.77. The firm has a market cap of $179.65 million, a PE ratio of -1.49 and a beta of -0.17. Eledon Pharmaceuticals, Inc. has a 52-week low of $2.30 and a 52-week high of $5.54.
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.20. As a group, sell-side analysts predict that Eledon Pharmaceuticals, Inc. will post -0.81 EPS for the current year.
Eledon Pharmaceuticals Profile
(
Free Report)
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
See Also
Before you consider Eledon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.
While Eledon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
